 |
|||||
| lose weight | |||||
| NEWS | |||||
|
TRANSCEND-T2D-1: Retatrutide Demonstrates Superior Weight Loss and A1c Results ...
Eli Lilly's investigative GLP-1/GIP/glucagon triple agonist has outperformed placebo in patients with poorly-controlled T2D.
|
|||||
| See more results | Edit this alert | |||||
| You have received this email because you have subscribed to Google Alerts. |
 Receive this alert as RSS feed |
|
Send Feedback
|
